Concurrent validation of the relevant outcome scale for Alzheimer’s disease (ROSA) in mexican patients


  • E. Mariana Longoria-Ibarrola
  • G. Isaac Acosta-Castillo
  • Mauricio Rosales-Méndez
  • Paola Andrade-Calderón
  • Oscar San Pedro-Caligua
  • Ana Luisa Sosa-Ortiz



scale, dementia, Alzheimer´s disease, ROSA


Objective: the Relevant Outcome Scale for Alzheimer´s disease (ROSA) is a new brief multidimensional instrument. ROSA and three standard instruments were applied to assess cognitive, functional and behavioral manifestations in patients with Alzheimer’s disease and other dementias in order to establish its concurrent validity, analyzing correlation of ROSA´s evaluation areas with the corresponded standard instruments selected in the studied groups. Methods: we evaluated 101 patients with AD and other dementia diagnoses, with ROSA and three standard instruments Minimental State Examination (MMSE), Informant Questionnaire of Cognitive Decline in the Elderly (IQCODE) and the Neuropsychiatric Inventory (NPI). The Spearman correlation coefficient was examined in the different groups included, comparing specific ROSA´s sections with MMSE, IQCODE and NPI. Results: the best Spearman correlation coefficients were found for the AD group, followed for the FTD and DM groups, and the worst were for VD. In the case of the correlation coefficient for ROSA´s behavioral section with NPI, it was only significant for the FTD group. Conclusions: we studied the ROSA´s concurrent validation in patients with several dementia types, even when this scale was specifically developed for Alzheimer´s patients. We got similar results in patients with AD and FTD, nevertheless ROSA´s behavioral section correlation with NPI was only significant for the FTD group. We recommend validating ROSA on Mexican patients and exploring its possible utility for FTD patients.



How to Cite

Longoria-Ibarrola, E. M., Acosta-Castillo, G. I., Rosales-Méndez, M., Andrade-Calderón, P., Pedro-Caligua, O. S., & Sosa-Ortiz, A. L. (2014). Concurrent validation of the relevant outcome scale for Alzheimer’s disease (ROSA) in mexican patients. Archivos De Neurociencias, 19(1), 3–8.



Original Articles